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Abstract 
Cervicogenic headache (CEH) is a secondary headache which affects 1.0–4.6 % of the population. Although the costs 
are unknown, the health consequences are substantial for the individual; especially considering that they often suffers 
chronicity. Pharmacological management has no or only minor effect on CEH. Thus, we aim to assess the efficacy of 
chiropractic spinal manipulative therapy (CSMT) for CEH in a single-blinded placebo-controlled randomized clini-
cal trial (RCT). According to the power calculations, we aim to recruit 120 participants to the RCT. Participants will be 
randomized into one of three groups; CSMT, placebo (sham manipulation) and control (usual non-manual manage-
ment). The RCT consists of three stages: 1 month run-in, 3 months intervention and follow-up analyses at the end of 
intervention and 3, 6 and 12 months. Primary end-point is headache frequency, while headache duration, headache 
intensity, headache index (frequency × duration × intensity) and medicine consumption are secondary end-points. 
Primary analysis will assess a change in headache frequency from baseline to the end of intervention and to follow-
up, where the groups CSMT and placebo and CSMT and control will be compared. Due to two group-comparisons, 
the results with p values below 0.025 will be considered statistically significant. For all secondary end-points and 
analyses, the significance level of 0.05 will be used. The results will be presented with the corresponding p values and 
95 % confidence intervals. To our knowledge, this is the first prospective manual therapy three-armed single-blinded 
placebo-controlled RCT to be conducted for CEH. Current RCTs suggest efficacy in headache frequency, duration and 
intensity. However a firm conclusion requires clinical single-blinded placebo-controlled RCTs with few methodologi-
cal shortcomings. The present study design adheres to the recommendations for pharmacological RCTs as far as pos-
sible and follows the recommended clinical trial guidelines by the International Headache Society.
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Background
The prevalence of cervicogenic headache (CEH) is low 
and varies from 1.0 to 4.6  % in the general population, 
depending on the applied diagnostic criteria, i.e. 1.0  % 
if 6 and 4.6 % if 5 diagnostic criteria of the Cervicogenic 
Headache International Study Group are fulfilled, and 
2.5 % if the criteria of the International Headache Soci-
ety (IHS) are applied (Table  1) (Nilsson 1995a; Pareira 
Monteriro 1995; Sjaastad et  al. 1998; Sjaastad and Bak-
keteig 2008; Headache Classification Subcommittee of 
the International Headache Society 2013). Headache dis-
orders have substantial health and socio-economic costs 
(Vos et  al. 2012). However, no studies have exclusively 
investigated the costs for CEH.
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CEH is a symptomatic headache characterized by pri-
marily chronic and usually unilateral headache as well 
as symptoms and signs of neck involvement (Sjaastad 
et  al. 1998; Sjaastad and Fredriksen 2000; Bogduk and 
Govind 2009). CEH is often worsened by neck move-
ment, sustained awkward head position, external pres-
sure over the upper cervical or occipital region on the 
symptomatic side (Pareira Monteriro 1995; Sjaastad 
and Fredriksen 2000). Abolition of the headache follow-
ing diagnostic anaesthetic blocks of cervical structures 
or local factors in the neck gives evidence that the pain 
is attributed to a neck disorder or lesion (Pareira Mon-
teriro 1995; Sjaastad and Bakketeig 2008; Bogduk and 
Govind 2009).
Pharmacological management is the first treatment 
option for CEH despite the limited effect. The risk of 
medication overuse due to frequent headache attacks 
represents therefore a major health hazard and both 
direct and indirect cost concerns. The prevalence of med-
ication overuse headache (MOH) is 1–2 % in the general 
population (Grande et al. 2008; Aaseth et al. 2008; Jensen 
and Stovner 2008), i.e. about half the population suffering 
chronic headache (15 headache days or more per month) 
have MOH (Lundqvist et al. 2012).
Diversified technique and Gonstead method are the 
two most commonly used chiropractic manipulative 
treatment modalities in the profession, used by 91 and 
59  % of chiropractors, respectively (Cooperstein 2003; 
Cooperstein and Gleberson 2004), along with other man-
ual and non-manual interventions, i.e., soft tissue tech-
niques, spinal and peripheral mobilization, rehabilitation, 
postural corrections and exercises as well as general 
nutrition and dietetic advises.
A few spinal manipulative therapy (SMT) randomized 
controlled trials (RCTs) using the Diversified technique 
have been conducted for CEH, suggesting an effect on 
headache frequency, headache duration, headache inten-
sity and medicine consumption (Nilsson 1995b; Nilsson 
et al. 1997; Jull et al. 2002; Haas et al. 2004, 2010; Boru-
siak et  al. 2010). However, common for previous RCTs 
are the methodological shortcomings, such as; inaccurate 
headache diagnosis, i.e., questionnaire-based diagno-
ses used are imprecise (Rasmussen et  al. 1991), inade-
quate or no randomization procedure involved, lack of 
Table 1 Diagnostic criteria for cervicogenic headache by the Cervicogenic Headache International Study Group
a It is obligatory that one or more of phenomena 1a–c are present
Major criteriaa
 1. Symptoms and signs of neck involvement
  a. Precipitation of head pain, similar to the usually occurring one:
   i. By neck movement and/or sustained awkward head positioning, and/or:
   ii. By external pressure over the upper cervical or occipital region on the symptomatic side
  b. Restriction of range of motion (ROM) in the neck
  c. Ipsilateral neck, shoulder, or arm pain of a rather vague nonradicular nature or, occasionally, arm pain of a radicular nature.
 2. Confirmatory evidence by diagnostic anesthetic blockade
 3. Unilaterality of the head pain, without side shift
Head pain characteristics
 4. Moderate-severe, non-throbbing, and non-lancinating pain, usually starting in the neck. Episodes of varying duration, or: fluctuating, continuous 
pain
Other characteristicsof some importance
 5. Only marginal effect or lack of effect of indomethacin. Only marginal effect or lack of effect of ergotamine and sumatriptan. Female sex. Not infre-
quent occurrence of head or indirect neck trauma by history, usually of more than only medium severity.
Other features of lesser importance
 6. Nausea. Phonophobia and photophobia. Dizziness. Ipsilateral “blurred vision”. Difficulties swallowing. Ipsilateral oedema, mostly in the periocular 
area
Diagnostico criteria for cervicogenic headache by the International Classification of Headache Disorders-II
 A. Pain, referred from a source in the neck and perceived in one or more regions of the head and/or face, fulfilling criteria C and D
 B. Clinical, laboratory and/or imaging evidence of a disorder or lesion within the cervical spine or soft tissues of the neck known to be, or
generally accepted as, a valid cause of headache
 C. Evidence that the pain can be attributed to the neck disorder or lesion based on at least one of the following:
  i Demonstration of clinical signs that implicate a source of pain in the neck
  ii Abolition of headache following diagnostic blockade of a cervical structure or its nerve supply using placebo- or other adequate controls
 D. Pain resolves within 3 months after successful treatment of the causative disorder or lesion
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placebo group, and primary and secondary end-points 
not pre-specified (Vernon 1995; Chaibi and Russell 2012; 
Fernandez-de-las-Penas et  al. 2006). In addition, previ-
ous RCTs mostly included participants with infrequent 
CEH attacks and did not adhere to the guidelines from 
the IHS (Tfelt-Hansen et al. 2000; Silberstein et al. 2008). 
At present, no RCTs have applied the Gonstead method. 
Thus, considering the methodological shortcomings in 
previous RCTs, a clinical placebo-controlled RCT with 
improved methodological quality remains to be con-
ducted for CEH.
Although CEH is the headache we best understand, 
the SMT mechanism of action is unknown. It is argued 
that CEH might originate from a complexity of nocicep-
tive afferent responses involving the upper cervical spine 
(C1, C2 and C3), leading to a hypersensitivity state of the 
trigeminal pathway conveying sensory information for 
the face and much of the head (Kerr 1972; Bogduk 2004). 
Research has thus, suggested that SMT may stimulate 
neural inhibitory systems at different spinal cord levels 
and might activate various central descending inhibitory 
pathways (McLain and Pickar 1998; Vernon 2000; Vice-
nzino et  al. 2001; Boal and Gillette 2004; De Camargo 
et al. 2011). However, although the proposed physiologi-
cal mechanisms are not fully understood, there are likely 
additional unexplored mechanisms which could explain 
the effect that SMT has on mechanical pain sensitisation.
The objective is to investigate the efficacy of CSMT 
vs. placebo (sham manipulation) and controls (continue 
usual pharmacological management without receiving 
manual intervention) for CEH in a RCT.
Methods and design
This is a single-blinded placebo-controlled RCT with 
three parallel groups (CSMT, placebo and control). 
Our primary hypothesis is that CSMT gives at least 
25 % reduction in average number of headache days per 
month (30  days) as compared to no change in the pla-
cebo and the control group from baseline to the end of 
intervention, and we expect the same reduction to main-
tain at 3, 6 and 12 months follow-up. If the CSMT treat-
ment is effective, it will be offered to participants whom 
received placebo or control after study completion, i.e., 
after 12 months follow-up. The study will adhere to the 
recommended clinical trial guidelines from the IHS 
(Tfelt-Hansen et  al. 2000; Silberstein et  al. 2008), and 
the methodological CONSORT guidelines (Moher et al. 
2010).
Patient population
Participants will be recruited in the period September 
to October 2012 through Akershus University Hospital 
and Innlandet Hospital Trust, Norway. Participants will 
receive posted information about the project followed by 
a short telephone interview.
Eligible participants are between 18 and 70 years of age 
and have at least one headache attack per month. Par-
ticipants are diagnosed according to at least three major 
criteria not including occipital nerve blockage from the 
diagnostic criteria of the Cervicogenic Headache Interna-
tional Study Group (Sjaastad et al. 1998; Knackstedt et al. 
2010). All participants are diagnosed by a neurologist.
Exclusion criteria are contraindication to SMT, spinal 
radiculopathy, pregnancy, depression and CSMT within 
the previous 12  months. Participants whom during the 
RCT receive any manual interventions by physiothera-
pists, chiropractors, osteopaths or other health pro-
fessionals to treat musculoskeletal pain and disability, 
including massage therapy, joint mobilization and manip-
ulation (French et  al. 2011), changed their prophylactic 
headache medicine or pregnancy will be withdrawn from 
the study at that time and be regarded as drop-outs.
In response to initial contact, participants fulfilling the 
inclusion criteria will be invited to further assessment by 
the chiropractic investigator. The assessment includes an 
interview and a physical examination with special empha-
sis on the whole spinal column. Oral and written infor-
mation about the project will be provided in advance and 
written consent will be obtained from all accepted partici-
pants during the interview by the clinical investigator. In 
accordance with good clinical practice, all patients will be 
informed about the harms and benefits as well as possible 
adverse reactions of the intervention primarily includ-
ing local tenderness and tiredness on the treatment day. 
No serious adverse events have been reported for the chi-
ropractic Gonstead method (Cassidy et  al. 2008; Tuchin 
2012). Participants randomized into active or placebo 
interventions, will undergo a full spine radiographic exam-
ination and be scheduled for 12 intervention sessions. The 
control group will not be exposed to this assessment.
Clinical randomized controlled trial
The clinical RCT consists of 1  month run-in and 
3 months intervention. Time profile from baseline to the 
end of follow-up will be assessed (Fig. 1).
Run‑in
The participants will fill in a validated diagnostic paper 
headache diary one month prior to intervention which 
will be used as baseline data for all participants (Russell 
et  al. 1992; Lundqvist et  al. 2009). The validated diary 
includes questions directly related to the primary and 
secondary end-points. X-rays will be taken in standing 
position in the anterior–posterior and lateral planes of 
the entire spine. The X-rays will be assessed by the clini-
cal investigator.
Page 4 of 9Chaibi et al. SpringerPlus  (2015) 4:779 
Randomization
Prepared sealed lots with the three interventions, i.e., 
active treatment, placebo and the control group, will 
be divided into four sub-groups by age and gender, i.e., 
woman and men, 18–39 and 40–70  years, respectively. 
Participants will be equally allocated to one of the three 
arms by only allowing participants to draw one lot. The 
blocked randomization will be administrated by an exter-
nal trained party without the involvement from the clini-
cal investigator.
Intervention
Active treatment consists of CSMT using the Gonstead 
method (Cooperstein 2003). A specific contact, high-
velocity, low-amplitude, short-lever, with no recoil post 
spinal adjustment directed to spinal biomechanical dys-
function diagnosed by standard chiropractic tests.
The placebo intervention consists of sham manipu-
lation, i.e., a broad non-specific contact, low-velocity, 
low-amplitude sham push manoeuvre in a non-inten-
tional and non-therapeutic directional line. All the 
non-therapeutic contacts will be performed outside 
the spinal column with adequate joint slack and with-
out pre-tension so no joint cavitations occur (Chaibi 
et al. 2015). In some sessions, the participant lay either 
prone on a Zenith 2010 HYLO bench with the investi-
gators standing at the participant’s right side with his 
left palm placed on the participant’s right lateral scapu-
lar edge with the other hand reinforcing. In other ses-
sions, the investigator will stand at the participant’s left 
side and place his right palm over the participant’s left 
scapular edge with the other hand reinforcing, delivering 
a non-intentional lateral push manoeuvre. Alternatively, 
the participant lay in the same side posture position as 
the active treatment group with the bottom leg straight 
and top leg flexed with top leg’s ankle resting on the 
bottom leg’s knee fold, in preparation for a side posture 
push move, which will be delivered as a non-intentional 
push in the gluteal region. The sham manipulation alter-
natives will be equally interchanged among the placebo 
participant’s according to protocol during the 12 weeks 
treatment period to strengthen the study validity. Both 
the active and the placebo group will receive the same 
structural and motion assessment prior to and after each 
intervention. No additional co-interventions or advises 
will be given to participants during the trial period. The 
treatment period will include 12 consultations, i.e., twice 
per week the first three weeks followed by once a week 
the next two and once every second week until 12 weeks 
are reached. Fifteen minutes will be allocated per con-
sultation for each participant. All interventions will be 
administered by an experienced chiropractor (AC) at 
Akershus University Hospital and Innlandet Hospital 
Trust, Norway.
The control group will continue usual care, i.e., phar-
macological management without receiving manual 
intervention by the clinical investigator. The same exclu-
sion criteria apply for the control group during the whole 
study period.
Blinding
Participants whom receive active or placebo intervention 
will fill in a de-blinding questionnaire after each of the 12 
treatment sessions administrated by an external trained 
independent party with no involvement from the clinical 
investigator, i.e., providing a dichotomous “yes” or “no” 
answer as to the question whether active treatment was 
received. This response was followed by a second ques-
tion regarding how certain they were that active treat-
ment was received on a 0–10 numeric rating scale (NRS), 
where 0 represents absolutely uncertain and 10 repre-
sents absolute certainty. The control group and the clini-
cal investigator can for obvious reasons not be blinded 
(Bang et al. 2004; Johnson 2005; Chaibi et al. 2015).
Months  Post-treatment and follow-up analysis
               0                      1                            4                                     5                           8                           11                     17 
   CSMT      
    Baseline            Treatment           Post-treatment            3-months            6-months           12-months 
               0                       1                            4                                    5                            8                           11                     17 
Interview      Randomizaon Placebo              
                       Baseline            Treatment           Post-treatment            3-months            6-months           12-months 
                    0                      1                            4                                     5                           8                           11                     17 
   Control 
     Baseline                                          Post-treatment            3-months            6-months           12-months 
Fig. 1 Flow-chart of study
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Follow‑up
Follow-up analysis will be conducted on the end-points 
measured after the end of intervention and 3, 6 and 
12 months follow-up. During this period all participants 
will continue to fill in a diagnostic headache diary and 
return it on a monthly basis. In the case of unreturned 
diary or missing values in the diary, the participants will 
be contacted immediately upon detection to minimize 
recall bias. Participants will be contacted by phone to 
secure compliance.
Primary and secondary end‑points
The primary and secondary end-points are listed in 
Table  2. The end-points adhere to the recommended 
IHS clinical trial guidelines (Tfelt-Hansen et  al. 2000; 
Silberstein et  al. 2008). We define number of head-
ache days to be primary end-point and expect at least 
25 % reduction in average number of days from base-
line to the end of intervention, with the same level of 
reduction maintaining at follow-up. Based on previous 
reviews on CEH, a 25 % reduction is considered to be 
a conservative estimate (Chaibi and Russell 2012). A 
25  % reduction from baseline to the end of interven-
tion and follow-up is also expected in secondary end-
points for headache duration, headache intensity, and 
headache index, where the index is calculated as mean 
days with headache (30 days) × mean headache dura-
tion (hours per day)  ×  mean intensity (0–10 NRS). 
A 50  % reduction in medication consumption from 
baseline to the end of intervention and to follow-up is 
expected.
Data processing
A flowchart of the participants is shown in Fig. 2. Base-
line demographic and clinical characteristics will be 
tabulated as means and standard deviations (SD) for 
continuous variables and proportions and percentages 
for categorical variables. Each of three groups will be 
described separately. Primary and secondary end-points 
will be presented by suitable descriptive statistics in each 
group and for each time point. Normality of end-points 
will be assessed graphically and transformation will be 
considered if necessary.
Change in primary and secondary end-points from 
baseline to the end of intervention and to follow-up will 
be compared between active and placebo and active and 
control group. Null-hypothesis states that there is no sig-
nificant difference between the groups in average change, 
while the alternative hypothesis states that a difference of 
at least 25 % exists.
Due to follow-up period, repeated recordings of 
primary and secondary end-points will be available, 
and analyses of trend in primary and secondary end-
points will be of main interest. Intra-individual cor-
relations (cluster effect) are likely to be present in data 
with repeated measurements. Cluster effect will thus be 
assessed by an intra-class correlation coefficient (ICC) 
quantifying the proportion of total variation attribut-
able to the intra-individual variations. The trend in 
end-points will be assessed by a linear regression model 
for longitudinal data (linear mixed model) to correctly 
account for possible cluster effect. Linear mixed model 
handles unbalanced data, enabling all available infor-
mation from randomized patients to be included, also 
from drop-outs. Regression models with fixed effects 
for time component and group allocation as well as 
the interaction between the two will be estimated. The 
interaction will quantify possible differences between 
groups regarding time trend in the end-points and serve 
as an omnibus test. Random effects for patients will be 
included to adjust the estimates for intra-individual 
correlations. Random slopes will be considered. The 
Table 2 Primary and secondary end-points
The data analysis is based on the run-in period vs. end of intervention. Point 11–40 will be duplicate of point 1–10 above at respectively 3, 6 and 12 months follow-up
Primary end-points
 1. Number of headache days in active treatment vs. placebo group
 2. Number of headache days in active treatment vs. control group
Secondary end-points
 3. Headache duration in hours in active treatment vs. placebo group
 4. Headache duration in hours in active treatment vs. control group
 5. Self-reported VAS in active treatment vs. placebo group
 6. Self-reported VAS in active treatment vs. control group
 7. Headache index (frequency × duration × intensity) in active treatment vs. placebo group
 8. Headache index in active treatment vs. control group
 9. Headache medication dosage in active treatment vs. placebo group
 10. Headache medication dosage in active treatment vs. control group
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linear mixed models will be estimated by SAS PROC 
MIXED procedure. The two pairwise comparisons will 
be performed by deriving individual time point contrasts 
within each group with the corresponding p values and 
95 % confidence intervals (CI).
Both per-protocol and intention-to-treat analyses 
will be conducted if relevant. All analyses will be per-
formed by a statistician, blinded for group allocation 
and participants. All adverse effects will also be regis-
tered and presented. Participants who experience any 
sort of adverse effects during the trial period will be 
entitled to call the prime investigator on the project 
cell phone. The data will be analyzed with SPSS v22 
and SAS v9.3. Because of two group-comparisons in a 
primary end-point, p values below 0.025 will be con-
sidered statistically significant. For all secondary end-
points and analyses, a significance level of 0.05 will 
be used. Missing values might appear in incomplete 
interview questionnaires, incomplete headache diaries, 
missed intervention sessions and/or due to drop-outs. 
The pattern of missingness will be assessed and missing 
values handled adequately.
Power calculation
Sample size calculations are based on the results in a 
recently published group comparison study on topira-
mate (Silberstein et  al. 2004). We hypothesize that 
the mean difference in reduction of number of days 
with headache per month between active and the pla-
cebo group is 2.5  days. The same difference is assumed 
between active and the control group. Standard deviation 
for reduction in each group is assumed to be equal 2.5. 
Under the assumption of on average 10 headache days 
per month at baseline in each group and no change in 
the placebo or control group during the study, 2.5  days 
reduction corresponds to a reduction by 25  %. As pri-
mary analysis includes two group-comparisons, we set a 
significance level at 0.025. A sample size of 20 patients is 
required in each group to detect a statistical significant 
mean difference in reduction of 25  % with 80  % power. 
Potenal parcipants informed
and invited for screening (n=150) 
No response through 
inial contact (n=10) 
Randomizaon (n=120)
CSMT (n=40) Placebo (n=40) Control (=40)
Follow-up assessment  
Post-treatment (n=25) 
3-months (n=25) 
6-months (n=25) 
12-months (n=25) 
Follow-up assessment  
Post-treatment (n=25) 
3-months (n=25) 
6-months (n=25) 
12-months (n=25) 
Follow-up assessment  
Post-treatment (n=25) 
3-months (n=25) 
6-months (n=25) 
12-months (n=25) 
Screening inclusion and exclusion 
criteria (n=140) 
Dropout (n=15) Dropout (n=15) Dropout (n=15)
Not meeng inclusion 
criteria (n=10) 
Potenal eligible parcipants 
criteria (n=130) 
Did not want to 
parcipate (n=10) 
Fig. 2 Expected participants flow diagram
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To allow for drop-outs, the investigators plan to recruit at 
least 120 participants.
Ethics
The study has been approved by the Norwegian 
Regional Committee for Medical Research Ethics (REK) 
(2010/1639/REK) and the Norwegian Social Science Data 
Services (11–77). The declaration of Helsinki is otherwise 
followed. All data will be anonymised while participants 
must give oral and written informed consent, including 
consent to publish all obtained data. Insurance is pro-
vided through “The Norwegian System of Compensation 
to Patients” (NPE) which is an independent national body, 
set up to process compensation claims from patients who 
have suffered an injury as a result of treatment under the 
Norwegian health service. A stopping rule is defined for 
withdrawing participants from this study in accordance 
with recommendations in the CONSORT extension for 
Better Reporting of Harms (Ioannidis et  al. 2004). If a 
participant reports to their chiropractor or research staff 
a severe adverse event, he or she will be withdrawn from 
the study and referred to their General Practitioner or 
hospital emergency department depending on the nature 
of the event. Data will be stored in a locked cabinet at the 
Research Centre, Akershus University Hospital, Norway, 
for 5 years.
Discussion
Methodological considerations
Current SMT RCTs on CEH suggest treatment efficacy 
regarding headache frequency, headache duration and 
headache intensity. However, a firm conclusion requires 
clinical single-blinded placebo-controlled RCTs with 
few methodological shortcomings (Chaibi and Russell 
2012). Such studies should adhere to the recommended 
IHS clinical trial guidelines with headache frequency as 
primary end-point and headache duration, headache 
intensity, headache index and medication consump-
tion as secondary end-point (Tfelt-Hansen et  al. 2000; 
Silberstein et al. 2008). Headache index, combination of 
frequency, duration and intensity, gives an indication of 
the total level of suffering. Headache index has despite 
the lack of consensus been recommended as an accepted 
standard secondary end-point, thus, we included this as 
a secondary outcome (Bendtsen et  al. 1996; Silberstein 
et al. 2008; Hagen et al. 2009). The primary and second-
ary end-points will be collected prospectively in a vali-
dated diagnostic headache diary for all participants in 
order to minimize recalling bias (Russell et al. 1992; Lun-
dqvist et al. 2009).
To our knowledge, this is the first prospective manual 
therapy three-armed single-blinded placebo-controlled 
RCT to be conducted for CEH. The study design adheres 
to the recommendations for pharmacological RCTs as 
far as possible. RCTs that include a placebo and control 
group are advantageous to pragmatic RCTs that compare 
two active treatment arms. RCTs also provide the best 
approach for producing safety as well as efficacy data.
An unsuccessful blinding is a possible risk to the RCT. 
Blinding is often difficult as there is no single validated 
standardized chiropractic sham intervention which can 
be used as a control group to this date. It is however, 
necessary to include a placebo group in order to pro-
duce a true net effect of the active intervention. Con-
sensus about an appropriate placebo for a clinical trial 
of SMT among experts representing both clinicians and 
academics has, however, not be reached (Hancock et al. 
2006). No previous studies have to our knowledge, vali-
dated a successful blinding of a CSMT clinical trial with 
multiple treatment sessions. We intend to minimize this 
risk by following the proposed protocol for the placebo 
group.
The placebo response is furthermore high in pharma-
cological and assumed similarly high for non-pharma-
cological clinical studies, however, it might be higher in 
manual therapy RCTs were attention and physical con-
tact is involved (Meissner et al. 2013). Similarly, a natural 
concern with regards to attention bias will be involved for 
the control group as they are not being seen by anyone or 
not seen as much as the other two groups.
There are always risks for drop-outs due to various rea-
sons. As the trial duration is 16 months with a 12 months 
follow-up period, the risk for loss to follow-up is thus 
enhanced. Co-occurrence of other manual intervention 
during the trial period is another possible risk, as those 
whom receive manipulation or other manual physical 
treatments elsewhere during the trial period will be with-
drawn from the study and regarded as drop-outs at the 
time of violation. Participants are allowed to continue 
their usual medication throughout the trial.
The external validity of the RCT might be a weakness 
as there is only one investigator. However, we found 
that advantageous to multiple investigators, in order to 
provide similar information to participants in all three 
groups and manual intervention in the CSMT and 
the placebo group. Thus, we intend to eliminate inter-
observer variability which might be present if there 
are two or more investigators. Although the Gonstead 
method is the second most used technique among chi-
ropractors, we do not see an issue of concern when it 
comes to generalizability and external validity.
Recruiting participants to the study might however 
be a challenge due to the low prevalence in the general 
population and our strict exclusion criteria. A weak rep-
resentativeness of the study population might thus influ-
ence the results and generalizability.
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The internal validity is, however, strong by having 
one investigator. It reduces the risk of potential selec-
tion, information and experimental biases. Further-
more, all participants are diagnosed by an experienced 
neurologist and not by questionnaires. A direct contact 
through interview has higher sensitivity and specific-
ity as compared to questionnaire (Rasmussen et  al. 
1991). Individual motivational factors which can influ-
ence participant’s perception as well as personal pref-
erences when treating are both reduced by having one 
investigator. In addition, the internal validity is further 
strengthened by a concealed validated randomization 
procedure.
Conducting X-rays prior to the active and placebo 
interventions was found applicable in order to visualize 
posture, joint and disc integrity (Taylor 1993; Interna-
tional Chiropractic Assocoation Practicing Chiroprac-
tors’ Committee on Radiology Protocols (PCCRP) for 
biomechanical assessment of spinal subluxation in chiro-
practic clinical practice. 2009). As the total X-ray radia-
tion dose varies from 0.2–0.8 mSv, the radiation exposure 
was considered low (Cracknell and Bull 2006; Borretzen 
et  al. 2007). X-ray assessments were also found neces-
sary in order to determine if full spine X-rays are useful 
in future studies or not.
As we are unaware of the mechanisms of possible effi-
cacy, and both spinal cord and central descending inhibi-
tory pathways has been postulated, we see no reasons to 
exclude a full spine treatment approach for the interven-
tion group. It has furthermore been postulated that pain 
in different spinal regions should not be regarded as sep-
arate disorders but rather a single entity (Leboeuf et  al. 
2012). Similarly, including a full spine approach limits 
the differentiations between the CSMT and the placebo 
group. Thus, it might strengthen the likelihood of suc-
cessful blinding in the placebo group being achieved. In 
addition, all the placebo contacts will be performed out-
side the spinal column, thus, minimizing a possible spinal 
cord afferent input.
Innovative and scientific value
This RCT will highlight and validate the Gonstead CSMT 
for CEH, which has not previously been studied. If CSMT 
proves to be efficient, it will provide a non-pharmaco-
logical treatment option. This is especially important as 
pharmacological management for CEH has no or only 
minor effect. Thus, if CSMT works, it can really have an 
impact on CEH treatment. The study also bridges coop-
eration between chiropractors and physicians, which is 
important in order to make the healthcare more efficient. 
Finally, our method might be applied in future chiroprac-
tic and other manual therapy RCTs on headache.
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